DURIPANC is an investigator-initiated, exploratory, open-label, single-center study, and 18 subjects have enrolled in the study so far. The clinical trial is a joint collaboration between AIM, ...

Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by deploying Evinova’s AI-native platform in an effort to speed up clinical development.

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc. ("Astellas"), AstraZeneca and Bristol Myers Squibb to accelerate their global clinical ...

AstraZeneca (AZN) announced an update on their ongoing clinical study. AstraZeneca recently completed a clinical study titled ‘A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I ...

AstraZeneca has launched a new company to allow CROs and fellow Big Pharmas to pay to access its tried-and-tested digital solutions for running clinical trials. The standalone company, called Evinova, ...

The MarketWatch News Department was not involved in the creation of this content. Charlottesville, VA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The University of Virginia (UVA) today announced the signing of ...

OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical ...

Pharmaceutical giant AstraZeneca announced the launch of Evinova, a health technology business focused on bringing digital health solutions already in use globally by the pharma company to clinical ...